Trials / Enrolling By Invitation
Enrolling By InvitationNCT06637254
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 219 (estimated)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK31858 | HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma |
| DRUG | Placebo | the placebo comparator of study |
Timeline
- Start date
- 2024-10-22
- Primary completion
- 2026-03-22
- Completion
- 2026-09-20
- First posted
- 2024-10-15
- Last updated
- 2024-12-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06637254. Inclusion in this directory is not an endorsement.